Overview
The GLP-1 receptor agonist family has expanded rapidly in recent years. In laboratory research, three peptides dominate the current literature:
- Semaglutide — a single-receptor GLP-1 agonist
- Tirzepatide — a dual GIP + GLP-1 agonist
- Retatrutide — a triple GIP + GLP-1 + glucagon agonist
Receptor profiles
| Peptide | GLP-1 | GIP | Glucagon |
| -------------- | ----- | --- | -------- |
| Semaglutide | ✓ | | |
| Tirzepatide | ✓ | ✓ | |
| Retatrutide | ✓ | ✓ | ✓ |
Half-life (approximate, from published data)
- Semaglutide: ~165 h (≈1 week)
- Tirzepatide: ~120 h (≈5 days)
- Retatrutide: ~160 h (≈1 week)
This supports a once-weekly research dosing schedule for all three compounds in most preclinical protocols.
Typical research dose ranges
Figures below are drawn from published literature and are not clinical recommendations:
- Semaglutide: 0.25 – 2.4 mg weekly
- Tirzepatide: 2.5 – 15 mg weekly
- Retatrutide: 1 – 12 mg weekly
Use our dose calculator to convert these into your reconstituted volume.
For research purposes only. Not for human consumption. Not a medicinal product.